2018 top 100 enterprises list of China's pharmaceutical industry released the top three revenue generating secrets!

On August 25, the 2019 (36th) national pharmaceutical industry information annual conference hosted by China Pharmaceutical Industry Information Center opened in Lianyungang The conference solemnly released the list of top 100 enterprises of Chinese pharmaceutical industry in 2018, which attracted the attention of the industry Yangzijiang Pharmaceutical Group Co., Ltd., Guangzhou Pharmaceutical Group Co., Ltd and China Pharmaceutical Group Co., Ltd are among the top three According to the statistics and analysis of China Pharmaceutical Industry Information Center, the top 100 enterprises in 2018 continued their consistent strong growth momentum, with the main business income scale reaching 839.55 billion yuan, with a growth rate of 11.8% Under the leading role of the top 100 enterprises, pharmaceutical industry enterprises have maintained strong revenue capacity and sufficient development momentum In fact, there are evidences to follow The first half performance meeting just held by Yangzijiang pharmaceutical group shows that the cumulative output value and sales of Yangzijiang pharmaceutical group increased by 11.22% and 12.68% respectively year on year from January to June this year The group once again won the first place among the top ten industrial economy enterprises in the city The Yangtze River won the first place in the 2018 top 100 list of China's pharmaceutical industry released by the chamber of Commerce of medicine industry of all China Federation of industry and commerce And last year, there were a lot of remarkable things Most awesome is that R & D has achieved fruitful results, 10 approved by chemical drugs and Chinese medicine production, 2 innovative drugs have entered clinical research, and 5 varieties have achieved import substitution through the evaluation of the quality and efficacy of generic drugs, and the development of aftereffect has been further enhanced Like Yangzijiang pharmaceutical, Guangzhou Pharmaceutical Group is still in the second place Baiyunshan Pharmaceutical, a subsidiary of Guangzhou Pharmaceutical Group, achieved an operating revenue of 33.341 billion yuan in the first half of 2019, a year-on-year increase of 124.67%; a total profit of 3.212 billion yuan, a year-on-year increase of 6.66%; a net profit of 2.548 billion yuan, a year-on-year decrease of 2.73%; net profit attributable to shareholders of the company after deducting non recurring profit and loss The profit was 2.205 billion yuan, up 43.10% year on year Compared with the first half of 2018, the main reason for the growth of Baiyunshan's business performance in the reporting period is on the one hand the further development of its business in various sectors Among them, Wang Laoji health company, a wholly-owned subsidiary of Baiyunshan, implemented cost control and price maintenance measures and received government subsidies, achieving a large increase in profits; on the other hand, because the pharmaceutical company and Wang Laoji pharmaceutical industry were incorporated into Baiyunshan The scope of the merger increased the main business income and profit year on year China Pharmaceutical Group broke into the top three for the first time this year, ranking fourth last year In fact, the performance of Sinopharm group is also good, with six listed companies under Sinopharm group, including Sinopharm holding, Sinopharm, Sinopharm and Sinopharm According to the semi-annual performance report released by Sinopharm on the evening of August 21, the company's operating revenue reached 21.012 billion yuan in the first half of 2019, an increase of 11.99% year-on-year; the net profit attributable to shareholders of listed companies was 755 million yuan, an increase of 18.66% year-on-year It can be said that the top three are all big companies of Chinese pharmaceutical enterprises, which is also a microcosm of the increasingly obvious Matthew effect of Chinese pharmaceutical enterprises Attached list: Top 100 pharmaceutical enterprises of China in 2018